Abstract
The authors would like to note that the investigator affiliations have been corrected to reflect the actual affiliations of each author. The authors would also like to note an amendment to the first name of the second author. Nilo Azad was changed to reflect the full name of the author, which is Nilofer S. Azad as shown above. The original article has been corrected.
| Original language | English |
|---|---|
| Pages (from-to) | 1158 |
| Number of pages | 1 |
| Journal | Investigational New Drugs |
| Volume | 36 |
| Issue number | 6 |
| DOIs |
|
| Publication status | Published - 1 Dec 2018 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer (Investigational New Drugs, (2018), 10.1007/s10637-018-0663-0)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver